|
FY2025
12 months to Sep 30, 2025
|
FY2024
12 months to Sep 30, 2024
|
FY2023
12 months to Sep 30, 2023
|
FY2022
12 months to Sep 30, 2022
|
FY2021
12 months to Sep 30, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Product revenues | |||||
| Service revenues | |||||
| Clinical laboratory service revenues | |||||
| Total revenues | |||||
| Cost of product revenues | |||||
| Product revenues | |||||
| Clinical laboratory service revenues | |||||
| Total cost of product revenues | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Selling, general and administrative | |||||
| Research and development | |||||
| Impairment losses | |||||
| Total operating expenses | |||||
| LOSS FROM OPERATIONS | |||||
| Interest income | |||||
| Transaction costs allocated to warrant liabilities | |||||
| Unrealized gain on change in fair value of warrants classified as a liability | |||||
| Unrealized loss on change in fair value of warrants classified as a liability - warrant modification | |||||
| Unrealized loss on change in fair value of warrants classified as a liability-warrant modification | |||||
| Loss on issuance of warrants | |||||
| Other expense, net | |||||
| Loss before provision for income taxes | |||||
| Income tax provision benefit | |||||
| Net loss from continuing operations | |||||
| Net loss from discontinued operations, net of tax | |||||
| NET LOSS | |||||
| Less: Net loss attributable to noncontrolling interest | |||||
| NET LOSS attributable to BNB Plus Corp. | |||||
| Deemed dividend related to warrant modifications | |||||
| NET LOSS attributable to common stockholders | |||||
| Net loss per share attributable to common stockholders-continuing operations - basic (in dollars per share) | |||||
| Net loss per share attributable to common stockholders-continuing operations - diluted (in dollars per share) | |||||
| Net loss per share attributable to common stockholders-discontinued operations - basic (in dollars per share) | |||||
| Net loss per share attributable to common stockholders-discontinued operations - diluted (in dollars per share) | |||||
| Net loss income per share attributable to common stockholders - basic (in dollars per share) | |||||
| Net loss income per share attributable to common stockholders - diluted (in dollars per share) | |||||
| Weighted average shares outstanding- basic (in shares) | |||||
| Weighted average shares outstanding- diluted (in shares) | |||||
Loading...